Malaria vaccines - how and when to proceed?

Trends in Parasitology

Volumn 25, Issue 12, 2009, Pages 535-537

  Craig, Alister G ^a   Holder, Anthony A ^b   Leroy, Odile Y ^c   Ventura, Roland A ^c  

^a LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^b NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^c STATENS SERUM INSTITUT   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

APICAL MEMBRANE ANTIGEN 1; CIRCUMSPOROZOITE PROTEIN; IMMUNOLOGICAL ADJUVANT; MALARIA VACCINE; SUBUNIT VACCINE;

ANTIBODY TITER; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ANTIMALARIAL ACTIVITY; CELLULAR IMMUNITY; CLINICAL TRIAL; CODON; DRUG ANTIGENICITY; DRUG EFFICACY; DRUG LEGISLATION; DRUG SAFETY; DRUG TOLERABILITY; EARLY INTERVENTION; EPIDEMIOLOGY; ERYTHROCYTE; GOOD MANUFACTURING PRACTICE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; LIFE CYCLE; MALARIA; MALARIA CONTROL; PARASITE TRANSMISSION; PATENT; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SEQUENCE HOMOLOGY; SHORT SURVEY; T LYMPHOCYTE; VACCINATION; VACCINATION REACTION; VACCINE PRODUCTION;

ANTIGENS, PROTOZOAN; CLINICAL TRIALS AS TOPIC; HUMANS; MALARIA; MALARIA VACCINES; PLASMODIUM;

EID: 70449130389     PISSN: 14714922     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pt.2009.09.005     Document Type: Short Survey

References (18)

1. Sullivan M. Moving candidate vaccines into development from research: lessons from HIV. Immunol. Cell Biol. 87 (2009) 366-370
2. Ballou W.R., et al. Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine. Lancet 1 (1987) 1277-1281
3. Herrington D.A., et al. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Nature 328 (1987) 257-259
4. Moorthy V., et al. A vaccine against malaria: a substantial step forward. Lancet 373 (2009) 1411-1412
5. Pierce S.K., and Miller L.H. World Malaria Day 2009: what malaria knows about the immune system that immunologists still do not. J. Immunol. 182 (2009) 5171-5177
6. Casares S., and Richie T.L. Immune evasion by malaria parasites: a challenge for vaccine development. Curr. Opin. immunol. 21 (2009) 321-330
7. Coppel R.L. Vaccinating with the genome: a Sisyphean task?. Trends Parasitol. 25 (2009) 205-212
8. Collins C.R., et al. An inhibitory antibody blocks interactions between components of the malarial invasion machinery. PLoS Pathog. 5 (2009) e1000273. http://www.plospathogens.org 10.1016/j.pt.2009.07.008
9. Luke T.C., and Hoffman S.L. Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuated Plasmodium falciparum sporozoite vaccine. J. Exp. Biol. 206 (2003) 3803-3808
10. Mueller A.K., et al. Genetically modified Plasmodium parasites as a protective experimental malaria vaccine. Nature 433 (2005) 164-167
11. Arnot D.E., et al. Comparative testing of six antigen-based malaria vaccine candidates directed toward merozoite-stage Plasmodium falciparum. Clin. Vaccine Immunol. 15 (2008) 1345-1355
12. Bergmann-Leitner E.S., et al. Critical evaluation of different methods for measuring the functional activity of antibodies against malaria blood stage antigens. Am. J. Trop. Med. Hyg. 75 (2006) 437-442
13. Miura K., et al. Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines. Vaccine 26 (2008) 193-200
14. Reed Z.H., et al. Comparison of immunogenicity of five MSP1-based malaria vaccine candidate antigens in rabbits. Vaccine 27 (2009) 1651-1660
15. Roestenberg M., et al. Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02. PLoS One 3 (2008) e3960. http://www.plosone.org/ 10.1371/journal.pone.0003960
16. Spring M.D., et al. Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A. PLoS One 4 (2009) e5254. http://www.plosone.org/ 10.1371/journal.pone.0005254
17. Thera M.A., et al. Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: results of a phase 1 randomized controlled trial. PLoS One 3 (2008) e1465. http://www.plosone.org/ 10.1371/journal.pone.0001465
18. Sanderson F., et al. Blood-stage challenge for malaria vaccine efficacy trials: a pilot study with discussion of safety and potential value. Am. J. Trop. Med. Hyg. 78 (2008) 878-883